INTRODUCTION {#s1}
============

Patients with Proteus syndrome (PS) have severe, progressive overgrowth that can affect nearly any region of the body ([@MCS004549BIEC1]). It is progressive and causes death ([@MCS004549BIEC21]), either by distortion or compression of vital structures by overgrown tissues, thromboembolism ([@MCS004549BIEC11]), respiratory disease associated with pulmonary cysts ([@MCS004549BIEC20]; [@MCS004549BIEC14]), or malignant transformation in an overgrown tissue such as a parotid tumor, ovarian cystadenoma, or testicular tumor ([@MCS004549BIEC5]). Common syndromic manifestations include large superficial or deep lipomatous overgrowths, intellectual disability, seizures and other neurological problems, and severe skeletal deformities with skull overgrowth, kyphoscoliosis, asymmetric macrodactyly and valgus, or varus deformities of the knees. The cerebriform connective tissue nevus (CCTN) of the soles found in many patients is a specific, but not pathognomonic finding. It makes weight-bearing and footwear uncomfortable, and hygiene is difficult to maintain ([@MCS004549BIEC6]).

A somatic variant in the *AKT1* gene---c.49G \> A, p.Glu17Lys---is the only reported cause of PS ([@MCS004549BIEC15]). AKT1 is a serine-threonine kinase that participates in the AKT/PI3K/mTOR pathway: The p.Glu17Lys variant constitutively activates the protein, limiting apoptosis and promoting growth, among other effects ([@MCS004549BIEC4]). Miransertib (ARQ 092) is an oral, allosteric, selective pan-AKT inhibitor that inhibits both active and inactive forms of AKT. In in vitro and in vivo experiments, it demonstrated antiproliferative activity in cancer and in cells derived from patients with *PIK3CA*-related overgrowth syndrome (PROS) and PS ([@MCS004549BIEC16]; [@MCS004549BIEC30]). An abstract describing patients with ovarian cancers bearing *PIK3CA* or *AKT1* variants treated with miransertib reported favorable efficacy and side effects ([@MCS004549BIEC10]). More recently, metastatic tumors and some skeletal deformities improved after 22 mo of treatment of a teenager with PS and metastatic ovarian cancer ([@MCS004549BIEC13]). The only available alternative treatments of PS are palliative. Presently, 29 participants with either PS or PROS have been treated with miransertib in two ongoing research projects and under compassionate use programs (B Schwartz, unpubl. data). Six of these individuals, all with PS, were treated with miransertib in a research project being run by the U.S. National Institutes of Health (NIH) ([@MCS004549BIEC12]). That study reached a pharmacodynamic endpoint of 50% inhibition of AKT in five of six treated patients and suggestions of efficacy for CCTN reduction and pain reduction, although these were secondary endpoints not evaluated for statistical significance. Based on these suggestions of efficacy and apparently tolerable adverse effects, we treated a young man with PS with miransertib on a compassionate use basis and report that experience here.

RESULTS {#s2}
=======

Clinical Presentation and Family History {#s2a}
----------------------------------------

The patient was born at 41 wk gestation by vaginal delivery weighing 3.6 kg with no prenatal complications. Both parents had learning difficulties; otherwise there was no relevant family history. His medical history was complicated by nonaccidental fractures of the femur, tibia, and clavicle at age 5 wk and care was assumed by the Public Guardian. His current foster parents brought him to genetics at age 16 mo with global developmental delay, overgrowth of the right frontal bone, and macrodactyly of the right middle finger. A clinical diagnosis of PS was based on the developmental delay, macrodactyly, and frontal overgrowth ([@MCS004549BIEC3]). Subsequent developments are listed in [Table 1](#MCS004549BIETB1){ref-type="table"}.

###### 

Clinical timeline

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Age (yr)   Clinical details
  ---------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  2          Left convergent strabismus\
             Clinically diagnosed lipomatous overgrowths of the right anterior abdominal wall, right axilla, and chin, with significant cosmetic deformity\
             Overgrowth of right leg requiring osteotomy with stapling of the distal femoral growth plate at age 31 mo\
             Amputation of overgrown left second and third toes

  3          Amputation of right third toe\
             Cerebriform connective tissue nevus of the soles\
             Vineland Adaptive Behavior Scales, Interview Edition, standardized with mean 100, 95% confidence interval ± 15, assessed at age 41 mo ([Supplement 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004549/-/DC1)) was 61 ± 6 (0.5th centile)

  4          Valgus deformity of right knee and varus deformity of the left knee\
             Varicose veins of right leg and continued growth of amputated toe stumps\
             Griffiths assessment at age 58 mo indicated 36 mo attainment

  5          Attention deficit hyperactivity disorder treated with methylphenidate.

  6          Factor V Leiden detected at National Institutes of Health on screening for thrombophilia, performed because of thromboembolism reported in other affected patients\
             Verbal IQ was 57 and performance IQ was 65 on WISC-IV

  7          Asymmetric testicular growth

  11         Superficial thrombophlebitis of varicose veins in the right leg

  15         Progressive valgus deformity of one knee and varus deformity of the other were treated successfully with bilateral epiphyseal stapling that enabled the patient to continue activities like walking and riding a bicycle

  17         Excision of benign right epididymal cystadenoma; another epididymal lump on that side has not grown and is being observed\
             Thrombosis of superficial varicose veins in the right leg at age 17 yr has been managed with clodipogrel and perioperative prophylaxis with enoxaparin sodium

  20         Repeated surgery to the turbinate bones and sinuses was planned for progressive overgrowth of the right frontal lesion, which was obstructing the right superomedial visual field, the nasal passages, and frontal sinus\
             Weight 60 kg, height 201 cm (\>97th centile), head circumference 59 cm (\>97th centile)\
             Middle finger lengths were right 11 cm (\>\>97th centile) and left 8.3 cm (∼75th centile), midhand lengths were right 23 cm (\>97th centile) and left 19 cm (∼60th centile); the right foot measured 26.5 cm (50th--75th centile), left 29 cm (\>97th centile); and upper to lower segment ratio was 0.94 and the arm span was 185 cm Blood pressure 116/58
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The Guardianship Board of the New South Wales Civil and Administrative Tribunal gave informed consent to applications by the patient and his foster parents for compassionate use of miransertib. This was approved by the Therapeutic Goods Administration, Australia, and the Quality Use of Medicines Committee of the John Hunter Hospital. After an initial dose of 10 mg daily the dose was increased after 1 mo to 30 mg per day and one month later to 50 mg per day (∼25 mg/m^2^).

Genomic Analysis {#s2b}
----------------

A mosaic c.49G \> A variant in *AKT1* was identified on Sanger sequencing of DNA from fibroblasts cultured from an affected area of skin ([Table 2](#MCS004549BIETB2){ref-type="table"}). Blood was not tested for this variant as the underlying variant is not usually found in blood ([@MCS004549BIEC15]), and DNA from affected tissue was available.

###### 

Variant table

  Gene     Chromosome   HGVS DNA reference                          HGVS protein reference   Variant type (substitution, deletion, etc.)   Predicted effect   dbSNP/dbVar ID   Genotype (heterozygous/homozygous)   ClinVar ID
  -------- ------------ ------------------------------------------- ------------------------ --------------------------------------------- ------------------ ---------------- ------------------------------------ ----------------
  *AKT1*   14           NM_005163.2(AKT1):c.49G \> A (p.Glu17Lys)   NP_001014432 E17K        Substitution                                  Activation         rs121434592      Heterozygous                         VCV000013983.2

Treatment Outcomes and Adverse Effects {#s2c}
--------------------------------------

The patient and his family reported that dryness of the mouth appeared soon after starting treatment, and this persisted unchanged. An episode of gingivostomatitis was treated with local analgesics. No previous similar lesions could be recalled. His pediatric dentist attributed loose painful dentition, noted after 3 mo treatment at the 25 mg/m^2^/day dose and attributable to known preexistent periodontal disease. The gingivostomatitis and painful dentition both resolved after a week of supportive treatment. Monthly blood biomarkers (see Methods; [Supplements 2a and 2b](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004549/-/DC1)) changed little in his nearly 1 yr of treatment. His hemoglobin was mildly low pretreatment and remained mildly low or normal during treatment. Serum bicarbonate was two units above the reference range on one occasion and one unit above on another. The only trends we noted were that of a slightly declining alkaline phosphatase (slope = −0.09 *r*^2^ = 0.784, *P* \< 0.0001) and a slightly rising fasting glucose (slope = 0.001, *r*^2^ = 0.49, *P* = 0.0037) and total cholesterol (slope = 0.0007, *r*^2^ = 0.48, *P* = 0.0044), although it is important to note that all three of these remained well within their normal ranges. ECG and echocardiogram at baseline and after 12 mo on miransertib 25 mg/m^2^/day were normal. There was a 14%--17% reduction in absolute area of the CCTN of the soles after 12 mo of treatment ([Fig. 1](#MCS004549BIEF1){ref-type="fig"}). Subjectively, the patient and his family have noted reduction in the volume of a lipomatous overgrowth of the right lower abdominal wall, and greater mobility and comfort of joints of the arms and hands. There was either improvement or stability in all indices of general mood and well-being assessed by questionnaire ([Supplements 3--5](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004549/-/DC1)). A repeat MRI scan 11 mo after commencement of treatment showed no obvious increase in the size of overgrown soft tissue and bone of the right frontal region or lipomatous overgrowth in the right abdominal wall ([Fig. 2](#MCS004549BIEF2){ref-type="fig"}).

![Areas of cerebriform lesion on soles before (*A*,*C*) and at follow-up after 12 mo treatment with miransertib 50 mg (25 mg/m^2^) per day (*B*,*D*), for *right* (*A*,*B*) and *left* (*C*,*D*) sole. Underneath the photographs are calculated areas of the lesion on each sole (see Methods).](MCS004549Bie_F1){#MCS004549BIEF1}

![Representative MRI photographs from before treatment and after 11 mo treatment. (*A*) Sagittal brain T1 MRI from baseline (*left*) and after 11 mo (*right*) showing no obvious progression of skull deformity or new lesion. (*B*) Axial T2 abdominal fat--saturated MRI from baseline (*left*) and after 11 months (*right*) showing dilatation of inferior vena cava (\*) and renal veins. (*C*) Baseline abdominal wall axial T1 fat saturation MRI scan showing lipomatous overgrowth (\*) of the right anterior abdominal wall. (*D*) After 11 mo treatment, abdominal wall axial T1 fat saturation MRI scan showing width of lipomatous overgrowth (\*) of the right anterior abdominal wall.](MCS004549Bie_F2){#MCS004549BIEF2}

DISCUSSION {#s3}
==========

This rare syndrome was first described in the modern medical literature in 1976 ([@MCS004549BIEC24]) and given its name in 1983 ([@MCS004549BIEC26]) to reflect the many forms adopted by a Greek sea god: Overgrowth can affect any area of the body, and the disorder is highly phenotypically heterogeneous ([@MCS004549BIEC2]). The overgrowth in PS is associated with an activation of the AKT1 protein ([@MCS004549BIEC15]). This name derives from the AKR laboratory mouse ([@MCS004549BIEC9]), which commonly had spontaneous leukemia and tumors including thymomas, cells from one of which were found to harbor a retrovirus designated AKT8 ([@MCS004549BIEC23]). The provirus sequence included part of a mouse host oncogene called v-akt, and in humans an orthologous sequence was identified in a gene named *AKT1*, which was found to be amplified in gastric adenocarcinomas ([@MCS004549BIEC22]). *AKT1* is mutated in a number of human tumors (COSMIC database), and in essentially all reports, the variant is the same as the variant that is found in the mosaic state in individuals with PS. This variant causes ligand-independent activation of the AKT1 signal, downstream from tyrosine kinase growth factor receptors in the AKT/PIK3CA/mTOR pathway ([@MCS004549BIEC4]). Miransertib is an allosteric inhibitor of AKT1 that has been shown in vitro to regulate the growth of tumors that have this variant. It has also been shown to inhibit AKT1 signaling in cells from patients with PS and a phase 0/1 pharmacodynamic study has shown an acceptable adverse effects profile and some preliminary data for efficacy. Based on these data and given the serious medical issues in this patient, compassionate use was considered to be appropriate.

His initial dose was about 5 mg/m^2^/day, similar to the dosing of the NIH study ([@MCS004549BIEC12]). This was escalated to 15 mg/m^2^/day and then 25 mg/m^2^/day, as he had no recognizable adverse effects other than a dry mouth that appeared on the lower doses and persisted throughout treatment. There were transient gingivostomatitis and loose, painful teeth, which appeared to resolve spontaneously; viral studies were not performed. In the lower-dose NIH study, grade 1 mucositis (CTCAE criteria) was observed four times ([@MCS004549BIEC12]). We monitored a number of clinical laboratory values for adverse effects, none significantly changed from normal to abnormal. There were some subtle trends of glucose, cholesterol, and alkaline phosphatase that were statistically significant, but are of uncertain clinical significance. One grade 1 hyperglycemia was observed in the NIH study. In contrast to the slight decline in alkaline phosphatase observed in this young man, there was a single occurrence of grade 2 elevation in the NIH study. There was a single observation of grade 1 cholesterol elevation in the NIH study. All three of these parameters remained within normal ranges in the subject of this report. His D-dimer levels were abnormal before treatment and remained abnormal.

We evaluated the individual for signs of the apparent benefit of treatment. The area of the CCTN lesion of the foot was decreased, which is consistent with the results shown in the phase 0/1 pharmacodynamic trial ([@MCS004549BIEC12]). The radiologist did not appreciate any enlargement of any of the overgrowth that was evaluable on the pre- and post-treatment MRI scans. The foster parents believed that the lipomas had decreased in volume. There was either improvement or stability in all indices of general mood and well-being assessed by the questionnaire.

The rarity and slow rate of progression of PS pose considerable challenges to the design of studies to measure the efficacy of any treatment. Long-term clinical trials, with novel study designs, will need to be undertaken to assess the benefits and adverse effects of chronic treatment. Until such trials can be completed, small studies and anecdotal reports of treated individuals are useful to begin to understand the risks and benefits of primary treatment of this disease. The results we report here are consistent with some evidence of benefit and modest apparent adverse effects. As in any other report of anecdotal data, caution must be exercised in interpreting the data, but in individuals such as the young man reported here, we conclude that the compassionate use was appropriate and we are continuing his treatment based on the assessment by his care providers and foster parents of the risks and benefits of this experimental treatment at the 25 mg/m^2^/day dosing level.

METHODS {#s4}
=======

Baseline whole-body MRI, full blood count, clotting studies with D-dimers, liver function tests, urea electrolytes creatinine, calcium magnesium phosphate, glucose, HbA1C, lipids, urinalysis, ECG, and echocardiogram were performed at baseline within a month before the commencement of treatment, and selected blood tests were repeated monthly. The patient\'s family was given a comprehensive list of side effects previously reported with miransertib and asked to report on the appearance of any of these (or other) symptoms.

Whole-body MRI was repeated 1 yr after commencement of treatment and analyzed unblinded by a radiologist for apparent changes in deformity and overgrowth. Two-dimensional photographs available for the cerebriform lesions on the soles before treatment and after 12 mo of treatment ([Fig. 1](#MCS004549BIEF1){ref-type="fig"}) were analyzed by Dermapix software ([www.quantificare.com](www.quantificare.com)). This quantified the area of the sole covered by the lesion ([Fig. 1](#MCS004549BIEF1){ref-type="fig"}). The Self-reported Pain Intensity Index ([@MCS004549BIEC19]; [@MCS004549BIEC7],[@MCS004549BIEC8]), Impact of Pediatric Illness Scale-Adult ([@MCS004549BIEC27], [@MCS004549BIEC28], [@MCS004549BIEC29]; [@MCS004549BIEC18]), and Adult Pain Interference Index form ([@MCS004549BIEC25]; [@MCS004549BIEC17]) were collated with parental questionnaires and were analyzed for marked or progressive changes without statistical analysis.

ADDITIONAL INFORMATION {#s5}
======================

Database Deposition and Access {#s5a}
------------------------------

The results have been deposited to COSMIC (<https://cancer.sanger.ac.uk/cosmic>) under accession number COSP31880. The variant was deposited to ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) and can be found under accession number VCV000013983.2.
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